Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR3 - TACC3 |
Therapy | Infigratinib |
Indication/Tumor Type | high grade glioma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 - TACC3 | high grade glioma | sensitive | Infigratinib | Case Reports/Case Series | Actionable | In a Phase II trial, Truseltiq (infigratinib) treatment resulted in limited efficacy with a 6-month progression-free survival (PFS) rate of 16.0%, a median PFS of 1.7 months, an objective response rate of 4.8% (1/21), and median overall survival of 6.7 months in patients with recurrent glioma harboring alterations in FGFR1 or FGFR3, however, resulted in stable disease with PFS of 30.2 months in a patient harboring FGFR3-TACC3 (PMID: 35344029; NCT01975701). | 35344029 |
FGFR3 - TACC3 | high grade glioma | sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387). | 22837387 |
FGFR3 - TACC3 | high grade glioma | sensitive | Infigratinib | Preclinical - Pdx | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of glioma harboring FGFR3-TACC3 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
(22837387) | Transforming fusions of FGFR and TACC genes in human glioblastoma. | Full reference... |
Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors | Full reference... | |
(35344029) | Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. | Full reference... |